— Know what they know.
Not Investment Advice
Also trades as: JUPWW (NASDAQ)

JUPW NASDAQ

Jupiter Wellness, Inc.
1W: +10.1% 1M: -13.8% 3M: +178.7% 1Y: +70.1%
$1.52
Last traded 2023-10-13 — delisted
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · $49.3M mcap · 9M float · 24.99% daily turnover
Smart Money Score
No convergence signal
Key Statistics
Market Cap$49.3M
52W Range0.305-1.64
Volume1,970,467
Avg Volume2,253,557
Beta0.28
Dividend
Analyst Ratings
No analyst coverage
Company Info
CEOBrian Scott John
Employees10
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
IPO Date2020-10-30
1061 East Indiantown Road
Jupiter, FL 33477
US
561 244 7100
About Jupiter Wellness, Inc.

Jupiter Wellness, Inc. develops cannabidiol (CBD) based medical therapeutics and wellness products. The company's clinical pipeline includes CaniDermRX (JW-100), a novel topical formulation containing CBD and aspartame for the treatment of eczema, dermatitis, and actinic keratosis; JW-101, a prescription product for the treatment of burns; and JW-200, a non-prescription lotion/lip balm for the treatment of symptoms of cold sores. It also manufactures, distributes, and markets a line of consumer products, such as CBD-infused sunscreen under the CaniSun brand; CBD-infused skin care lotion under the CaniSkin brand; and products for the dermatological treatments of pain and inflammation under the CaniDermRX brand. The company was formerly known as CBD Brands, Inc. Jupiter Wellness, Inc. was incorporated in 2018 and is headquartered in Jupiter, Florida.

Latest News
No recent news

Recent Insider Trades

NameTypeSharesPriceDate
Gulyas John P-Purchase 3,000 $3.50 2023-12-29
Boon Jarrett Adam 0 2023-09-01
Gulyas John P-Purchase 1,666,666 2023-08-31
Gulyas John P-Purchase 500 $0.78 2023-08-07
Gulyas John P-Purchase 1,000 $0.78 2023-08-07

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms